Who is this treatment actually for?

Not every painful hip qualifies, and knowing the difference early saves patients from pursuing a pathway that is not designed for their situation.

ChondroFiller is intended for focal, contained cartilage damage — specifically Grade III or IV lesions on the ICRS scale, meaning areas where cartilage has thinned severely or worn through to bone in a defined patch, rather than the widespread, diffuse loss seen in moderate-to-advanced osteoarthritis. Defect size is a practical boundary: lesions of roughly 3 cm² or smaller sit comfortably within the published indication, while clinical evaluation data extend the discussion to approximately 6 cm² in carefully selected cases.

The degree of background joint degeneration carries equal weight. Tönnis grading — a radiological measure of how much general wear is present in the hip — is a reliable guide here. Patients with Tönnis grade 0 or 1, meaning relatively well-preserved joint space, are considered suitable candidates. Tönnis grade 2 or 3, where significant narrowing or bone changes are already visible on imaging, represents a contraindication; evidence suggests success rates fall markedly in these groups.

The typical patient presenting for assessment is younger or mid-life, physically active, and carrying a focal defect arising from femoroacetabular impingement (FAI) correction or a past hip injury. A known allergy to collagen is a firm contraindication regardless of defect size or Tönnis grade.

Patients with more advanced degeneration are not without options — other pathways exist — but this particular treatment is not among them.

How ChondroFiller works as a collagen scaffold

The distinction between a scaffold and a filler matters clinically. ChondroFiller is an acellular type I collagen hydrogel — containing no added cells — that self-gels within three to five minutes of placement. Think of it as a temporary framework that invites the body's own repair cells to move in and fill the gap: the collagen matrix acts as a chemotactic signal, drawing progenitor cells from the surrounding tissue into the defect site where endogenous repair can begin.

As new tissue matures, the scaffold gradually resorbs. MRI studies use a scoring system called MOCART to measure structural change rather than just symptom relief; scores across treated joints have ranged from 70 to 87, suggesting active tissue ingrowth rather than passive void filling.

Because hip-specific clinical trials remain small, the cross-joint record provides important mechanistic context — if the recruitment biology is consistent across joint types, early hip findings become more interpretable rather than isolated anomalies. Knee cohort data and a 2025 study by Demmer et al. in wrist fractures both show measurable cartilage quality improvement using the same scaffold biology. This does not prove identical outcomes in the hip, but it supports the biological rationale underlying hip use.

What ChondroFiller does not do is lubricate or cushion the joint — that is the role of hyaluronic acid. It neither suppresses inflammation like a corticosteroid nor fills mechanical space the way a polyacrylamide hydrogel does. It is directed at the structural defect itself.

What published studies report for the hip

Published findings, taken together, point in a consistent direction — though from a modest evidence base that warrants honest framing.

The most cited hip-specific study, Mazek et al. (2021, n=24), evaluated arthroscopic application in patients with focal hip cartilage lesions and recorded significant clinical improvement at the six-month mark. That study has accumulated 20 citations and remains the primary published reference point for hip use.

Aggregate data drawn from hip cohorts indicate a mean improvement on the modified Harris Hip Score (mHHS) in the region of +33 points — a figure that exceeds the threshold widely accepted as the minimum for a change to be regarded as clinically meaningful. Post-operative MRI at six to eighteen months has shown defect filling exceeding 90% in hip cases, suggesting the scaffold is not simply occupying space but supporting active host-cell-mediated tissue formation within the treated area.

Knee data from two independent cohorts, reporting IKDC gains of approximately 30 points over three years — baseline scores in the high 40s rising to around 80 — provide parallel evidence that the scaffold's recruitment biology produces reproducible functional improvements across joint sites. This convergence matters when interpreting hip results that are individually small in scale.

Study sizes in the hip literature remain limited, no randomised controlled trial has been published for hip use, and most follow-up does not extend beyond two years. These are real constraints on confidence, and they are covered fully later in this article. What the published series can say is that, within their scope and in appropriately selected patients, the directional findings — functional improvement and MRI-confirmed tissue response — are encouraging and internally consistent across independent investigators.

How it compares to other cartilage treatment options

Microfracture is a bone-marrow stimulation technique that creates small channels through the subchondral bone, triggering a local healing response. Published series have reported reoperation rates of up to 41%, and the tissue produced is typically fibrocartilage — mechanically inferior to the hyaline-like cartilage that healthy joints contain.

Autologous cell implantation (ACI and its matrix-based variant, MACI) is the established surgical benchmark for focal defect repair. It involves two separate procedures — harvest and implantation — and comparative datasets have reported complication rates of up to 17% and reoperation rates of up to 37%. It remains a recognised option for larger or more complex defects, but it carries the burden of a staged surgical pathway.

Comparative data from the April 2025 Clinical Evaluation Report place ChondroFiller cohorts alongside these figures: complication rates approaching zero and reoperation rates in the 3–8% range. Those numbers sit in the same comparative table as microfracture and ACI/MACI data, but they come from non-randomised cohorts rather than head-to-head trials — a distinction that matters when drawing conclusions from them.

Hyaluronic acid and polyacrylamide hydrogel (such as Arthrosamid) serve a different purpose altogether. Both address symptoms — lubrication or mechanical cushioning — rather than the structural defect itself. For patients who are not suitable for scaffold treatment, or where symptom management is the primary goal, they occupy a legitimate but distinct role; comparing them with ChondroFiller is not straightforward because they are not trying to do the same thing.

PRP, microfragmented adipose tissue (mFAT), and bone marrow aspirate concentrate (BMAC) are biologic support options with an emerging, if variable, evidence base. They may create a more favourable biological environment around a defect, but none are designed to fill a focal structural lesion in the way a collagen scaffold is.

What the treatment pathway involves

For patients identified as suitable candidates, ChondroFiller is administered as an ultrasound-guided outpatient injection — no general anaesthetic or hospital admission is needed.

Assessment before treatment typically involves MRI to characterise the defect's size, depth, and location, alongside a review of radiological grading to confirm that surrounding cartilage and the wider joint are in a condition likely to support the scaffold's integration. This step is not merely administrative: the published candidacy criteria — focal Grade III/IV lesions in a joint without advanced degeneration — exist because outcomes in appropriate patients differ meaningfully from outcomes in those who fall outside them.

The injection itself uses real-time image guidance to place the collagen scaffold accurately within the prepared defect. The gel self-sets in situ within a few minutes of placement, conforming to the defect shape rather than requiring surgical fixation.

After treatment, a period of protected weight-bearing is usually advised to allow the scaffold to integrate with the surrounding tissue. Published protocols typically suggest this phase lasts several weeks, after which low-impact activity can be gradually reintroduced — though the precise timeline should always be agreed with the treating clinician based on individual findings rather than assumed from general guidance. Return to higher-impact activity and sport follows a phased rehabilitation programme spanning several months.

Arthroscopic implantation of ChondroFiller in an operating theatre is a separate surgical pathway for which different procedural considerations apply.

Gaps in the evidence and what to weigh up

The outpatient injection route and the arthroscopic implantation route share the same scaffold material and the same biological mechanism — but their published evidence bases are not equal. The hip trial data underpinning the outcomes discussed earlier in this article, including the Mazek et al. 24-patient cohort and the functional score improvements summarised in the April 2025 Clinical Evaluation Report, were collected from arthroscopic procedures in theatre settings. Injection-specific hip evidence is thinner: the biological rationale is consistent, and the scaffold behaves predictably across delivery routes, but hip-specific published data for the outpatient injection pathway have not yet accumulated to the same degree.

The other limitations are worth stating plainly and briefly, without rehearsing them in full: no randomised controlled trial has been published for hip use; published follow-up does not yet reliably extend beyond two years; and the available study populations have been small. For UK patients, ChondroFiller carries CE marking as a Class III medical device in Europe; it is not FDA-approved and is not routinely available outside Europe.

None of this disqualifies the treatment for well-selected patients — but it does define the edges of what the current evidence can confirm. The meaningful question for someone considering the injection pathway is not whether the collagen scaffold works in general, but whether the injection-route evidence is sufficient to support a decision given their specific defect, joint status, and activity goals. That weighing requires individual clinical assessment — not general figures — and an image-guided evaluation is the appropriate starting point.